Home / Stocks / APUS

APUS insider trading

Apimeds Pharmaceuticals US, Inc. — open-market insider buys and $1M+ sells from SEC Forms 3, 4 and 5.
Insider buys · 24 mo
3
Bought · 24 mo
$2.1M
Buys · last 90 days
0 · $0
Most recent buy
2025-05-15

Cluster buy detected

3 insiders bought APUS within a short window (2025-05-12→2025-05-13), $2.1M in total — cluster score 38/100. Members see the buyers, the score breakdown and the chart.

See the cluster

Recent insider filings

FiledInsiderTypeSharesPriceValue
2025-05-15Kim Christophercluster
Chairman and CMO
Bought27,500$1.83$50k
2025-05-14Koo Jakapcluster
Director
Bought28,500$1.99$57k
2025-05-14Inscobee Inc.cluster
10% owner
Bought500,000$4.00$2.0M

Most active insider buyers

InsiderRoleBuysTotal bought
Inscobee Inc.10% owner1$2.0M
Koo JakapDirector1$57k
Kim ChristopherChairman and CMO1$50k

See APUS on the chart

Every insider buy and sell for APUS plotted on the price, the full two-year history, cluster scores and daily updates — in the members area, $29/month. A free quarterly sample of the whole dataset needs no account.

Open the browserFree sample
Data from the SEC EDGAR ownership filings, refreshed daily. Only open-market purchases (transaction code P) and sales of $1M or more are shown; grants, option exercises and tax withholding are excluded because they run on schedules set years earlier. Not investment advice.